Australia Lists Celltrion’s Truxima For Cancer

Reimbursement Limited To Chemotherapy Program

Celltrion Healthcare’s Truxima has become the second rituximab biosimilar to be listed on Australia’s Pharmaceutical Benefits Schedule. But unlike Sandoz’ Riximyo version, Truxima is only eligible for oncology indications under a chemotherapy funding scheme.

Doctor_Syring_Australia
Australia has listed Celltrion's Truxima rituximab biosimilar for reimbursement under a chemotherapy program • Source: Shutterstock

Celltrion Healthcare’s Truxima (rituximab) has been listed on Australia’s Pharmaceutical Benefits Schedule from 1 January this year. But unlike Sandoz’ Riximyo rival to Roche’s MabThera reference biologic, Truxima is only listed for oncology use under the PBS’ Efficient Funding of Chemotherapy, or EFC, program that provides funding for chemotherapy drugs that are administered through infusion or injection at public or private hospitals.

Prescriptions for all rituximab brands, including Truxima, Riximyo and MabThera, under the EFC program are subject to streamlined authority. This...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Biosimilars

Making The UK A Leading Biosimilar Launch Destination – Realistic Or Optimistic?

 

Experts discussed the UK government’s commitment to make the country a desirable destination for companies to launch their biosimilars at a recent conference hosted by Medicines UK.

Room For Improvement? EU Industry Prepares Feedback For SPC Manufacturing Waiver Review

 
• By 

As the European Commission prepares a formal evaluation of the SPC manufacturing waiver, the generics and biosimilars industry is getting ready to provide detailed feedback on what works – and what doesn’t. At Medicines for Europe’s legal affairs conference, delegates heard the latest updates.

Biocon’s Denosumab Biosimilar Approved In The UK As Competition Grows In Europe

 

Denosumab biosimilar ranks are filling up in Europe as approvals flood in. Yet, little is known about the launch dates.

Pertuzumab Leader Henlius Receives EU Accreditation For Production Lines

 
• By 

Shanghai Henlius Biotech has received EMA GMP certification for its HLX14 and HLX11 biosimilar production lines, paving the way for faster market entry in the EU and reinforcing its global manufacturing credentials.

More from Products

MSN Labs Swerves 2026 US Entresto Patent Ahead Of Separate July 15 Expiry

 
• By 

Novartis has filed an immediate appeal after a US district court ruled that MSN Labs would not infringe one of its key patents shielding its $7.8bn Entresto brand, and denied the originator injunctive relief.

UK Sitagliptin Prices Shoot Up In June

 
• By 

Multiple strengths of sitagliptin saw average price increases that topped our rundown of UK generic pricing data in June.

Biocon’s Denosumab Biosimilar Approved In The UK As Competition Grows In Europe

 

Denosumab biosimilar ranks are filling up in Europe as approvals flood in. Yet, little is known about the launch dates.